GleamWall
中文EN

BFRI Biofrontera Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1858685 · Fiscal year ends 12/31

Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY17.8%
TTM net income YoY61.6%
TTM EPS YoY76.4%
Revenue 3-yr CAGR16.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-14.2%
Net margin-13.8%
FCF margin-17.2%
EBITDA margin-14.0%

Returns

ROE-988.4%
ROA-28.8%
ROIC (approx.)—
Asset turnover2.09x

Leverage & solvency

Liabilities / assets75.2%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.1%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$9.07M$12.00M$10.08M$17.10M$6.99M$9.03M$8.59M$12.56M
R&D expense$450,000$448,000$900,000$787,000$854,000$870,000$1.21M$783,000
SG&A expense$12.46M$9.63M$10.99M$8.52M$10.05M$10.53M$8.65M$8.20M
Operating income-$6.50M-$524,000-$4.32M$4.56M-$6.28M-$5.08M-$4.55M-$1.71M
Interest expense——————$120,000—
Pretax income-$6.42M-$581,000-$4.75M$5.64M-$6.64M-$5.30M-$4.20M-$1.40M
Income tax$4,000$23,000—$0$6,000$21,000-$1,000-$3,000
Net income-$6.42M-$604,000-$4.75M$5.64M-$6.65M-$5.32M-$4.20M-$1.40M
EBITDA-$6.50M-$524,000-$4.26M$4.62M-$6.28M-$5.08M-$4.52M-$1.17M
EPS (basic)-0.42-0.05-0.41—-0.62-0.57-0.47—
EPS (diluted)-0.42-0.05-0.41—-0.62-0.57-0.47—
Weighted avg. shares (diluted)15.28M12.92M11.68M—10.78M9.35M8.87M—
Balance sheet
Cash & equivalents$3.22M$4.66M$6.32M$6.39M$3.42M$7.24M$1.78M$5.91M
Receivables$4.79M$5.54M—$7.29M————
Inventory$1.73M$1.10M$1.23M$1.43M$4.33M$4.03M$6.53M$6.65M
Current assets$11.10M$12.44M$13.16M$18.08M$14.41M$18.82M$15.33M$20.70M
PP&E, net$2.11M$2.14M$2.17M$2.16M$20,000$37,000$59,000$80,000
Intangibles$2.53M$2.57M$2.61M$2.65M$22,000$26,000$31,000$35,000
Total assets$21.47M$24.06M$24.79M$28.56M$15.41M$20.14M$16.59M$22.10M
Current liabilities$14.24M$10.54M$10.92M$11.89M$12.55M$19.69M$10.96M$12.02M
Total liabilities$21.71M$18.11M$18.72M$18.08M$18.00M$24.81M$16.12M$17.67M
Shareholders' equity-$243,000$5.96M$6.07M$10.48M-$2.58M-$4.67M$469,000$4.43M
Shares outstanding17.95M14.21M11.87M11.65M11.65M10.14M8.87M8.87M
Cash flow statement
Operating cash flow-$1.43M-$1.66M-$70,000-$2.38M-$3.82M-$3.04M-$4.12M-$1.02M
Capital expenditure$9,000$0$5,000-$1,000-$1,000$1,000$3,000$1,000
Free cash flow-$1.44M-$1.66M-$75,000-$2.38M-$3.82M-$3.05M-$4.12M-$1.02M
Investing cash flow-$9,000$0-$5,000$3.00M$1,000-$1,000-$3,000-$1,000
Financing cash flow———$2.35M$0——$4.05M
Depreciation & amortization$0$0$55,000$62,000$0$0$29,000$538,000
Stock-based compensation$224,000$263,000$342,000$289,000$236,000$187,000$239,000$299,000

Free plan shows the latest 8 periods; Pro shows all 25 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.